The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Official Title: Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients
Study ID: NCT04348006
Brief Summary: Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Baghdad Hematology center - Baghdad Medical City, Baghdad, Bab-Almuadham, Iraq
Name: Ali M Jawad, PhD
Affiliation: Baghdad College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Bassam F Matti, PhD
Affiliation: Baghdad Medical City
Role: PRINCIPAL_INVESTIGATOR
Name: Tareq A Saleh, PhD
Affiliation: Baghdad Medical City
Role: STUDY_CHAIR
Name: Mahammed S Abbas, PhD
Affiliation: Baghdad Medical City
Role: STUDY_DIRECTOR
Name: Mohammed K Al-Qayyim, PhD
Affiliation: Baghdad Medical City
Role: PRINCIPAL_INVESTIGATOR
Name: Alaaldin S Naji, PhD
Affiliation: Baghdad College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Ammer F Majid, PhD
Affiliation: Baghdad Medical City
Role: PRINCIPAL_INVESTIGATOR
Name: Adil S Al-Oqaby, PhD
Affiliation: Baghdad Medical City
Role: PRINCIPAL_INVESTIGATOR
Name: Mazin A Shubir, PhD
Affiliation: Baghdad Medical City
Role: PRINCIPAL_INVESTIGATOR
Name: Hawraa D Jumaa, PhD
Affiliation: Baghdad Medical City
Role: PRINCIPAL_INVESTIGATOR
Name: Hayder A Fawzi, PhD
Affiliation: Al-Rasheed University College
Role: PRINCIPAL_INVESTIGATOR